---
schema_version: "secwatch.filing_event.v1"
accession: "0001503802-26-000006"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:13:09.230809+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Karyopharm defers debt payments, requires $25M equity raise to extend runway past mid-2026

## Summary
- Second Amendment to Credit Agreement defers June 2026 principal payment to September 10, 2026; interest due June 30 paid in kind.
- Minimum liquidity covenant reduced to $10M through Oct 10, 2026 (from $25M) conditional on $25M+ equity raise before June 10, 2026.
- Forbearance agreements with lenders and noteholders defer payment-related defaults through Sep 30, 2026, and liquidity covenant breaches through Oct 10, 2026.
- Phase 3 XPORT-EC 042 top-line data still expected mid-2026; the amendments aim to extend cash runway beyond that readout.

## SEC filing metadata
- accession: 0001503802-26-000006
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000150380226000006/0001503802-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000150380226000006/kpti-20260227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001503802-26-000006
- JSON: https://secwatch.observer/filing/0001503802-26-000006.json
- Plain text: https://secwatch.observer/filing/0001503802-26-000006.txt

## Key facts
- Material Agreements
  Karyopharm Therapeutics Inc. amended Second Amendment to Credit and Guaranty Agreement with Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent (effective 2026-02-27).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent
  - Effective: 2026-02-27
  source text: On February 27, 2026, Karyopharm Therapeutics Inc. (the “Company”) entered into the Second Amendment to Credit and Guaranty Agreement (the “Amendment”) with the lenders party thereto and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000150380226000006/0001503802-26-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.